Source link : https://www.newshealth.biz/health-news/experts-debate-aquila-trial-findings-in-smoldering-multiple-myeloma/
Treating high-risk smoldering multiple myeloma with single-agent daratumumab (Darzalex) delayed progression to active myeloma, according to findings from the phase III AQUILA trial presented at the American Society of Hematology (ASH) annual meeting. MedPage Today brought together three expert leaders in the field: Moderator Joseph Mikhael, MD, is joined by Amrita Krishnan, MD, and Tulio […]
Author : News Health
Publish date : 2024-12-16 19:12:41
Copyright for syndicated content belongs to the linked Source.